The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced solid tumors. This is a multicenter, open-label study consisting of two parts: dose escalation and tumor-specific expansion.
The main questions it aims to answer are:
* In the dose-escalation part: What is the safety, tolerability, PK profile, and preliminary efficacy of QLS5132 combination therapy, and what are the recommended dose(s) for expansion? * In the expansion part: What is the anti-tumor efficacy and further safety profile of QLS5132 combination therapy at the selected dose(s) in participants with specific tumor types?
Participants will:
* Be enrolled in sequential cohorts to receive QLS5132 in combination with other anticancer agents. * Undergo regular assessments for safety, drug concentration levels (PK), and tumor response.
Advanced solid tumors;
Measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1);
Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
Adequate organ function;
Previous treatment with drugs targeting CLDN6 (including antibody-drug conjugates [ADCs]), or any drug containing topoisomerase I inhibitors (including ADCs);
Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 2 weeks with small molecule and within 4 weeks with biologic before the first dose of QLS5132;
Progressive or symptomatic brain metastases;
Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection;
Parallel
QLS5132; Bevacizumab
DrugIntravenous infusion，Q3W
QLS5132; Platinum; Bevacizumab
DrugIntravenous infusion，Q3W
QLS5132; Olaparib; Bevacizumab
DrugOlaparib is oral; all others are intravenous infusion，Q3W
QLS5132; QL1706; QL2107
DrugIntravenous infusion，Q3W
QLS5132; QL1706; QL2107; Carboplatin; Cisplatin; Oxaliplatin
DrugIntravenous infusion，Q3W
Incidence and severity of adverse events
Incidence and severity of adverse events
Maximum tolerated dose (MTD)
Highest administered dose with \< 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants
Recommended Phase 2 Dose (RP2D)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
